A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

Summary

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Diabetes Mellitus, Type 2
• PreDiabetes
• Metabolic Syndrome

Eligibility basics and study details

Study type

Interventional

Phase

Not applicable

Ages

55 years and older

Sex

All

Healthy volunteers

Accepted

Sponsor

Cleerly, Inc.

Last updated on ClinicalTrials.gov

September 28, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites